Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 12 (December)

1. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
   Ophthalmology, 116(12): 2471-77.e1-2. [Abstract] [Full-text]
2. Verteporfin photodynamic therapy cohort study: report 2: clinical measures of vision and health-related quality of life.
   Ophthalmology, 116(12): 2463-70. [Abstract] [Full-text]
3. Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes.
   Ophthalmology, 116(12): e1-8. [Abstract] [Full-text]
4. Intraoperative pachymetric measurements during corneal collagen cross-linking with riboflavin and ultraviolet A irradiation.
   Ophthalmology, 116(12): 2336-9. [Abstract] [Full-text]
5. Voltage-gated potassium channels as therapeutic targets.
   Nat Rev Drug Discov, 8(12): 982-1001. [Abstract] [Full-text]
6. Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.
   Nat Rev Drug Discov, 8(12): 935-48. [Abstract] [Full-text]
7. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG.
   Pediatrics, 124(6): e1108-15. [Abstract] [Full-text]
8. Multidisciplinary management of Hunter syndrome.
   Pediatrics, 124(6): e1228-39. [Abstract] [Full-text]
9. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
   Hematol Oncol, 27(4): 198-202. [Abstract] [Full-text]
10. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
    Methods Mol Biol, 596: 291-323. [Abstract] [Full-text]
11. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes.
    Biomaterials, 31(5): 900-7. [Abstract] [Full-text]
12. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery.
    Biomaterials, 31(5): 952-63. [Abstract] [Full-text]
13. Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking.
    Biomaterials, 31(5): 975-87. [Abstract] [Full-text]
14. Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticles for enhanced tumor imaging in vivo: Synergistic effect of folate-receptor targeting and PEGylation.
    Biomaterials, 31(5): 934-42. [Abstract] [Full-text]
15. Local delivery of a collagen-binding FGF-1 chimera to smooth muscle cells in collagen scaffolds for vascular tissue engineering.
    Biomaterials, 31(5): 878-85. [Abstract] [Full-text]
16. Doxycycline loaded poly(ethylene glycol) hydrogels for healing vesicant-induced ocular wounds.
    Biomaterials, 31(5): 964-74. [Abstract] [Full-text]
17. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents.
    Biomaterials, 31(5): 923-33. [Abstract] [Full-text]
18. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
    Biomaterials, 31(5): 908-15. [Abstract] [Full-text]
19. Biodegradable branched poly(ethylenimine sulfide) for gene delivery.
    Biomaterials, 31(5): 988-97. [Abstract] [Full-text]
20. Tissue-specific gene delivery via nanoparticle coating.
    Biomaterials, 31(5): 998-1006. [Abstract] [Full-text]
21. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model.
    Biomaterials, 31(5): 916-22. [Abstract] [Full-text]
22. Polyketal microparticles for therapeutic delivery to the lung.
    Biomaterials, 31(5): 810-7. [Abstract] [Full-text]
23. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
    J Natl Cancer Inst, 101(23): 1624-32. [Abstract] [Full-text]
24. Longitudinal assessment of regional directed delivery in a rodent malignant glioma model.
    J Neurosurg Pediatr, 4(6): 592-8. [Abstract] [Full-text]
25. Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy.
    J Med Chem, 52(23): 7829-35. [Abstract] [Full-text]
26. Does a nanomolecule of Carboplatin injected periocularly help in attaining higher intravitreal concentrations?
    Invest Ophthalmol Vis Sci, 50(12): 5896-900. [Abstract] [Full-text]
27. Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
    Am J Clin Oncol, 32(6): 607-11. [Abstract] [Full-text]
28. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Am J Clin Oncol, 32(6): 559-63. [Abstract] [Full-text]
29. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.
    Mayo Clin Proc, 84(12): 1073-8. [Abstract] [Full-text]
30. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia.
    J Pediatr Hematol Oncol, 31(12): 955-6. [Abstract] [Full-text]
31. Acquired tracheoesophageal fistula during treatment for pediatric acute lymphoblastic leukemia.
    J Pediatr Hematol Oncol, 31(12): 960-2. [Abstract] [Full-text]
32. Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt.
    J Cell Physiol, 222(2): 433-43. [Abstract] [Full-text]
33. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.
    J Cell Physiol, 222(2): 401-10. [Abstract] [Full-text]
34. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.
    Cancer Res, 69(23): 8910-7. [Abstract] [Full-text]
35. Impact of computerized dosing on eptifibatide-associated bleeding and mortality.
    Am Heart J, 158(6): 1018-23. [Abstract] [Full-text]
36. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
    Lancet Oncol, 10(12): 1145-51. [Abstract] [Full-text]
37. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy.
    J Clin Endocrinol Metab, 94(12): 4907-13. [Abstract] [Full-text]
38. Androgen replacement therapy in Turner syndrome: a pilot study.
    J Clin Endocrinol Metab, 94(12): 4820-7. [Abstract] [Full-text]
39. Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine.
    Cancer Genet Cytogenet, 196(1): 96-104. [Abstract] [Full-text]
40. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Cancer Genet Cytogenet, 196(1): 31-7. [Abstract] [Full-text]
41. Expression of metabolically targeted biomarkers in endometrial carcinoma.
    Gynecol Oncol, 116(1): 21-7. [Abstract] [Full-text]
42. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
    Gynecol Oncol, 116(1): 126-30. [Abstract] [Full-text]
43. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.
    Gynecol Oncol, 116(1): 44-9. [Abstract] [Full-text]
44. No role for increased rectal compliance in pediatric functional constipation.
    Gastroenterology, 137(6): 1963-9. [Abstract] [Full-text]
45. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.
    Blood, 114(24): 5024-33. [Abstract] [Full-text]
46. A multidisciplinary protocol improves electrolyte replacement and its effectiveness.
    Am J Surg, 198(6): 911-5. [Abstract] [Full-text]
47. Using antimicrobial solution for irrigation in appendicitis to lower surgical site infection rates.
    Am J Surg, 198(6): 875-80. [Abstract] [Full-text]
48. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.
    Neurology, 73(23): 1957-62. [Abstract] [Full-text]
49. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
    J Clin Oncol, 27(35): 5972-8. [Abstract] [Full-text]
50. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    J Clin Oncol, 27(35): 5874-80. [Abstract] [Full-text]
51. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    J Clin Oncol, 27(35): 5881-6. [Abstract] [Full-text]
52. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue.
    J Clin Oncol, 27(35): 6033-40. [Abstract] [Full-text]
53. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    J Clin Oncol, 27(35): 5931-7. [Abstract] [Full-text]
54. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.
    J Clin Oncol, 27(35): 5986-92. [Abstract] [Full-text]
55. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    J Clin Oncol, 27(35): 6027-32. [Abstract] [Full-text]
56. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    J Clin Oncol, 27(35): 5906-10. [Abstract] [Full-text]
57. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
    J Clin Oncol, 27(35): 6012-8. [Abstract] [Full-text]
58. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
    J Clin Oncol, 27(35): 6006-11. [Abstract] [Full-text]
59. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
    J Clin Oncol, 27(35): 5911-8. [Abstract] [Full-text]
60. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease.
    Chest, 136(6): 1569-75. [Abstract] [Full-text]
61. Retro-orbital injection in adult zebrafish.
    J Vis Exp. [Abstract] [Full-text]
62. Aging, estrogens, and episodic memory in women.
    Cogn Behav Neurol, 22(4): 205-14. [Abstract] [Full-text]
63. Menopausal hormone therapy, hormone receptor status, and lung cancer in women.
    Semin Oncol, 36(6): 566-71. [Abstract] [Full-text]
64. Inadequate timing of prophylactic antibiotics in orthopedic surgery. We can do better.
    Acta Orthop, 80(6): 633-8. [Abstract] [Full-text]
65. In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring.
    Br J Cancer, 101(12): 2015-22. [Abstract] [Full-text]
66. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.
    Br J Cancer, 101(12): 1978-85. [Abstract] [Full-text]
67. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
    Br J Cancer, 101(12): 1972-7. [Abstract] [Full-text]
68. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
    Br J Cancer, 101(12): 1986-94. [Abstract] [Full-text]
69. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
    Br J Cancer, 101(12): 1995-2004. [Abstract] [Full-text]
70. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis.
    Vaccine, 28(3): 597-603. [Abstract] [Full-text]
71. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
    J Natl Cancer Inst, 101(24): 1682-95. [Abstract] [Full-text]
72. Long-term complete regression of nodal marginal zone lymphoma transformed into diffuse large B-cell lymphoma with highly active antiretroviral therapy alone in human immunodeficiency virus infection.
    Am J Med Sci, 338(6): 517-21. [Abstract] [Full-text]
73. Correlates of self-medication for anxiety disorders: results from the National Epidemiolgic Survey on Alcohol and Related Conditions.
    J Nerv Ment Dis, 197(12): 873-8. [Abstract] [Full-text]
74. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial.
    J Oral Maxillofac Surg, 68(1): 138-43. [Abstract] [Full-text]
75. Efficacy and safety of oral propranolol premedication to reduce reflex tachycardia during hypotensive anesthesia with sodium nitroprusside in orthognathic surgery: a double-blind randomized clinical trial.
    J Oral Maxillofac Surg, 68(1): 120-4. [Abstract] [Full-text]
76. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models.
    Int J Radiat Oncol Biol Phys, 76(1): 251-9. [Abstract] [Full-text]
77. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Cancer Res, 69(24): 9330-6. [Abstract] [Full-text]
78. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Cancer Res, 69(24): 9337-45. [Abstract] [Full-text]
79. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol.
    Cancer Invest, 28(1): 23-32. [Abstract] [Full-text]
80. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
    Blood, 114(25): 5136-45. [Abstract] [Full-text]
81. How I treat acute promyelocytic leukemia.
    Blood, 114(25): 5126-35. [Abstract] [Full-text]
82. A comparative study of topical 5-aminolevulinic acid incubation times in photodynamic therapy with intense pulsed light for the treatment of inflammatory acne.
    Dermatol Surg, 35(12): 1918-26. [Abstract] [Full-text]
83. Enhanced efficacy of photodynamic therapy with methyl 5-aminolevulinic acid in recalcitrant periungual warts after ablative carbon dioxide fractional laser: a pilot study.
    Dermatol Surg, 35(12): 1927-32. [Abstract] [Full-text]
84. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
    Int J Cancer, 126(2): 522-32. [Abstract] [Full-text]
85. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well.
    Int J Cancer, 126(2): 483-9. [Abstract] [Full-text]
86. Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors.
    Int J Cancer, 126(2): 583-8. [Abstract] [Full-text]
87. Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group.
    Int J Radiat Oncol Biol Phys, 76(1): 201-6. [Abstract] [Full-text]
88. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Int J Radiat Oncol Biol Phys, 76(1): 154-63. [Abstract] [Full-text]
89. RNAi as a new therapeutic strategy against HCV.
    Biotechnol Adv, 28(1): 27-34. [Abstract] [Full-text]
90. Preparation and characterization of folate-poly(ethylene glycol)-grafted-trimethylchitosan for intracellular transport of protein through folate receptor-mediated endocytosis.
    J Biotechnol, 145(1): 47-53. [Abstract] [Full-text]
91. Withaferin A targets heat shock protein 90 in pancreatic cancer cells.
    Biochem Pharmacol, 79(4): 542-51. [Abstract] [Full-text]
92. From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead?
    Biochem Pharmacol, 79(4): 525-34. [Abstract] [Full-text]
93. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial.
    Ann Rheum Dis, 69(1): 113-9. [Abstract] [Full-text]
94. Randomized clinical trial of co-amoxiclav versus no antibiotic prophylaxis in varicose vein surgery.
    Br J Surg, 97(1): 29-36. [Abstract] [Full-text]
95. Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 54(2): 206-11. [Abstract] [Full-text]
96. Transporters as drug targets: discovery and development of NPC1L1 inhibitors.
    Clin Pharmacol Ther, 87(1): 117-21. [Abstract] [Full-text]
97. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
    Blood, 114(26): 5251-5. [Abstract] [Full-text]
98. Transporters for drug delivery and as drug targets in parasitic protozoa.
    Clin Pharmacol Ther, 87(1): 122-5. [Abstract] [Full-text]
99. Pascal's Wager, infective endocarditis and the "no-lose" philosophy in medicine.
    Heart, 96(1): 15-8. [Abstract] [Full-text]
100. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
     J Clin Oncol, 27(36): 6207-12. [Abstract] [Full-text]
101. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
     J Clin Oncol, 27(36): 6101-8. [Abstract] [Full-text]
102. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
     J Clin Oncol, 27(36): 6129-34. [Abstract] [Full-text]
103. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
     J Clin Oncol, 27(36): 6222-8. [Abstract] [Full-text]
104. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
     J Clin Oncol, 27(36): 6117-23. [Abstract] [Full-text]
105. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.
     J Clin Oncol, 27(36): 6135-43. [Abstract] [Full-text]
106. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
     J Clin Oncol, 27(36): 6086-93. [Abstract] [Full-text]
107. Prophylactic antibiotics do not affect cultures in the treatment of an infected TKA: a prospective trial.
     Clin Orthop Relat Res, 468(1): 127-34. [Abstract] [Full-text]
108. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.
     Cancer Invest, 28(1): 33-7. [Abstract] [Full-text]
109. Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine.
     J Pharmacol Exp Ther, 332(1): 220-8. [Abstract] [Full-text]
110. Site-directed delivery of ferritin-encapsulated gold nanoparticles.
     Nanotechnology, 21(4): 045305. [Abstract] [Full-text]
111. The effects of growth hormone (GH) treatment on GH and insulin/IGF-1 signaling in long-lived Ames dwarf mice.
     J Gerontol A Biol Sci Med Sci, 65(1): 24-30. [Abstract] [Full-text]
112. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.
     Am J Epidemiol, 171(1): 113-22. [Abstract] [Full-text]
113. Fluid resuscitation does not improve renal oxygenation during hemorrhagic shock in rats.
     Anesthesiology, 112(1): 119-27. [Abstract] [Full-text]
114. The effect of metoclopramide in capsule enteroscopy.
     Dig Dis Sci, 55(1): 153-7. [Abstract] [Full-text]
115. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.
     J Cancer Res Clin Oncol, 136(2): 267-74. [Abstract] [Full-text]
116. Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
     J Cancer Res Clin Oncol, 136(2): 283-92. [Abstract] [Full-text]
117. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
     Ann Hematol, 89(2): 147-54. [Abstract] [Full-text]
118. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
     J Cancer Res Clin Oncol, 136(2): 233-41. [Abstract] [Full-text]
119. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.
     Ann Hematol, 89(2): 171-7. [Abstract] [Full-text]
120. Diclofenac-induced acute corneal melt after collagen crosslinking for keratoconus.
     Cornea, 29(1): 117-9. [Abstract] [Full-text]
121. Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats.
     Cancer Chemother Pharmacol, 65(3): 549-56. [Abstract] [Full-text]
122. Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
     Cancer Chemother Pharmacol, 65(3): 571-7. [Abstract] [Full-text]
123. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.
     Cancer Chemother Pharmacol, 65(3): 579-87. [Abstract] [Full-text]
124. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
     Cancer Chemother Pharmacol, 65(3): 509-14. [Abstract] [Full-text]
125. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
     Cancer Chemother Pharmacol, 65(3): 557-61. [Abstract] [Full-text]
126. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
     Cancer Chemother Pharmacol, 65(3): 491-5. [Abstract] [Full-text]
127. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice.
     Cancer Chemother Pharmacol, 65(3): 481-9. [Abstract] [Full-text]
128. Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma.
     Cancer Chemother Pharmacol, 65(3): 503-8. [Abstract] [Full-text]
129. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
     Cancer Chemother Pharmacol, 65(3): 527-36. [Abstract] [Full-text]
130. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
     Cancer Chemother Pharmacol, 65(3): 497-502. [Abstract] [Full-text]
131. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
     Cancer Chemother Pharmacol, 65(3): 437-46. [Abstract] [Full-text]
132. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
     Cancer Chemother Pharmacol, 65(3): 467-71. [Abstract] [Full-text]
133. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
     Cancer Chemother Pharmacol, 65(3): 473-80. [Abstract] [Full-text]
134. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
     Cancer Chemother Pharmacol, 65(3): 457-65. [Abstract] [Full-text]
135. An e-health driven laboratory information system to support HIV treatment in Peru: E-quity for laboratory personnel, health providers and people living with HIV.
     BMC Med Inform Decis Mak, 9: 50. [Abstract] [Full-text]
136. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
     J Acquir Immune Defic Syndr, 53(1): 86-94. [Abstract] [Full-text]
137. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.
     Am J Hematol, 85(1): 46-50. [Abstract] [Full-text]
138. Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation.
     Biotechnol Bioeng, 105(2): 421-30. [Abstract] [Full-text]
139. Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development.
     Biotechnol Bioeng, 105(2): 409-20. [Abstract] [Full-text]
140. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer.
     J Clin Oncol, 28(1): 35-42. [Abstract] [Full-text]
141. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
     J Clin Oncol, 28(1): 29-34. [Abstract] [Full-text]
142. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
     J Clin Oncol, 28(1): 69-76. [Abstract] [Full-text]
143. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
     J Clin Oncol, 28(1): 56-62. [Abstract] [Full-text]
144. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.
     J Clin Oncol, 28(1): 63-8. [Abstract] [Full-text]
145. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
     J Clin Oncol, 28(1): 154-9. [Abstract] [Full-text]
146. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
     J Clin Oncol, 28(1): 49-55. [Abstract] [Full-text]
147. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
     J Clin Oncol, 28(1): 8-14. [Abstract] [Full-text]
148. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
     J Clin Oncol, 28(1): 77-82. [Abstract] [Full-text]
149. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
     J Clin Oncol, 28(1): 83-91. [Abstract] [Full-text]
150. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.
     J Clin Oncol, 28(1): 114-8. [Abstract] [Full-text]
151. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
     J Surg Oncol, 101(1): 22-7. [Abstract] [Full-text]
152. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation.
     Stroke, 41(1): 72-7. [Abstract] [Full-text]
153. Mismatch-based delayed thrombolysis: a meta-analysis.
     Stroke, 41(1): e25-33. [Abstract] [Full-text]
154. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era.
     J Acquir Immune Defic Syndr, 53(1): 102-6. [Abstract] [Full-text]
155. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
     Cancer Chemother Pharmacol, 65(3): 589-95. [Abstract] [Full-text]
156. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis.
     Cornea, 29(1): 102-4. [Abstract] [Full-text]
157. Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
     J Cancer Res Clin Oncol, 136(2): 243-8. [Abstract] [Full-text]
158. Comparing childhood leukaemia treatment before and after the introduction of a parental education programme in Indonesia.
     Arch Dis Child, 95(1): 20-5. [Abstract] [Full-text]
159. Subcellular targeting strategies for drug design and delivery.
     Nat Rev Drug Discov, 9(1): 29-42. [Abstract] [Full-text]
160. Therapeutic potential of complement modulation.
     Nat Rev Drug Discov, 9(1): 43-56. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.